With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
In this video, Sarah DiGeronimo, NP, and Sydney Smith, PharmD, both from Dana-Farber Cancer Institute, Boston, Massachusetts, discuss tips for the management of common side effects resulting from…
NEW YORK (Reuters Health) – Premenopausal women with vitamin D deficiency are at increased risk for systolic hypertension in the coming years, according to study findings presented Thursday…
NEW YORK (Reuters Health) – Women who undergo vaginal hysterectomy and reconstructive pelvic surgery during the same operation are more likely to have perioperative complications than those who…
NEW YORK (Reuters Health) – In premenopausal women with breast cancer, adjuvant tamoxifen treatment significantly reduces the risk of contralateral breast cancer, according to results of a Swedish…
NEW YORK (Reuters Health) – Treatment with estrogen plus progestin does not seem to increase the risk of lung cancer per se, but it may increase the odds…
NEW YORK (Reuters Health) – Postmenopausal breast cancer patients taking aromatase inhibitors have increased risks for carpal tunnel syndrome and new or worsening arthralgia, two studies published online…
NEW YORK (Reuters Health) – The combination of pentoxifylline and vitamin E prevented radiation-induced lymphedema among breast cancer patients in a phase II trial in Sweden. The finding…
NEW YORK (Reuters Health) – Starting estrogen-progestogen therapy close to menopause may increase the risk of breast cancer, even with short-duration treatment, according to a report in the…
NEW YORK (Reuters Health) – Biomarkers of endothelial dysfunction are elevated in premenopausal women with migraine, which may help to explain the link between migraine and strokes, according…
NEW YORK (Reuters Health) – Findings from a systematic review indicate that while tamoxifen, raloxifene, and tibolone all reduce the risk of primary breast cancer, the drugs differ…
NEW YORK (Reuters Health) – Doubling the standard dose of fluvestrant improves the efficacy of the drug against breast cancer without affecting tolerability, new research suggests. Moroever, at…
